Gynecologic Cancer News

Lipophilic statins appeared associated with reduced mortality among women with ovarian cancer, according to results of a retrospective study presented at American Association for Cancer Research Virtual Annual Meeting II.

Secondary cytoreductive surgery significantly increased PFS among a cohort of women with recurrent ovarian cancer, according to results of a randomized, phase 3 study presented during the ASCO20 Virtual Scientific Program.

Minimally invasive surgical procedures appeared associated with an elevated risk for recurrence or death vs. open surgery among women with early-stage gynecologic cancers, according to results of two studies published in JAMA Oncology.

Secondary cytoreductive surgery conferred significant and clinically meaningful OS and PFS benefits for selected women with recurrent ovarian cancer, according to phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Avelumab appeared effective and safe for women with gestational trophoblastic tumors resistant to monochemotherapy, according to results of a single-arm phase 2 study presented during the ASCO20 Virtual Scientific Program.

The FDA approved several therapies for oncology or hematology indications.

Maintenance therapy with olaparib extended OS compared with placebo among women with platinum-sensitive, BRCA-mutated relapsed ovarian cancer, according to the final analysis of the randomized phase 3 SOLO-2 study scheduled for presentation during the ASCO20 Virtual Scientific Program.

Just a spoonful of sugar from Mary Poppins during cancer treatment might have an effect, after all.

The FDA expanded the approval of olaparib to include its use in combination with bevacizumab for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.

Healio spoke with Naoko Sasamoto, MD, MPH, from the Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Harvard Medical School, about her JAMA Oncology study that suggested breastfeeding as a potentially modifiable factor that may decrease risk for ovarian cancer independent of pregnancy alone – and what this means for clinicians.